The global vaso occlusive crisis associated with sickle cell disease drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The vaso-occlusive crisis associated with sickle cell disease is a common painful complication of sickle cell disease that occurs in adolescents and adults. The major factor driving the growth of the market is the rising prevalence of sickle cell disease across the globe. 

According to the Center for Disease Control and Prevention (CDC), in 2020, SCD affects approximately 100,000 Americans and occurs about 1 out of every 365 Black or African-American births. Additionally, SCD occurs among about 1 out of every 16,300 Hispanic-American births and about 1 in 13 Black or African-American babies is born with sickle cell trait (SCT). Hence, the increasing prevalence of SDC is increasing the risk for vaso occlusive crisis associated with sickle cell disease which in turn is driving the growth of the market. 

Some major players in the market include AstraZeneca Plc, Bristol-Myers Squibb Co., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2019, Novartis announced that it has received approval for Adakveo (crizanlizumab-tmca) from the US FDA. It is used for the treatment to reduce the frequency of vaso-occlusive crisis associated with sickle cell disease for patients age 16 years and older.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- AstraZeneca Plc, Bristol-Myers Squibb Co., and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Market Report by Segment

By Type

• SGD-2083 

• Crizanlizumab 

• PF-04447943 

• NVX-508 

• Others

By Application

• Hospital

• Clinic

• Other

Global Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa